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A B S T R A C T
Management of pelvic organ prolapse (POP) is a common and challenging task. Nowadays older women are
more active than they were in the past, and the development of POP disrupts quality of life and impairs social
and personal activities. The menopausal transition is a time of vulnerability, during which many women start
experiencing symptoms and signs of POP. The role of hormonal changes or of hormonal therapies in influencing
the development or progression of POP has been explored extensively. The management of POP requires con-
siderable clinical skills. Correct diagnosis and characterization of the prolapse and an identification of the in-
dividual woman’s most bothersome symptoms are the hallmark of appropriate initial management. Therapy is
multimodal and often multidisciplinary, and requires a competence in pelvic medicine and surgery. The in-
tegration of hormonal, non-hormonal and surgical strategies is important and needs to be adjusted to changing
circumstances on an individualized basis. When surgery is required, optimal management requires clinicians
who are familiar with the advantages and disadvantages of all the available strategies and who are able to use
these strategies in a tailored manner. Complex cases should be sent to specialist referral centers. Management of
POP should be integrated into the practice of healthcare professionals dealing in menopause.
1. Introduction
1.1. Definitions, epidemiology and clinical picture
Pelvic floor disorders include pelvic organ prolapse (POP), urinary in-
continence (UI), fecal incontinence, pelvic pain and sexual dysfunction.
POP is clinically defined as “the descent of one or more of the anterior
vaginal wall, posterior vaginal wall, the uterus (cervix) or the apex of the
vagina (vaginal vault or cuff scar after hysterectomy)” [1]. The incidence and
prevalence of POP have not been systematically investigated. While it is
estimated that nearly 50% of women will develop some form of prolapse,
only 10–20% of all women seek medical assistance [2]. The prevalence of
POP increases with age, with a peak incidence in women aged 60–69 [3].
POP can be identified in up to 50% of women upon vaginal inspection,
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but if POP is defined by the presence of clinically relevant symptoms, its
prevalence in the general population may range between 3% and 6%,
since mild or moderate POP is frequently asymptomatic [4].
The etiology of POP is multifactorial. Risk factors include preg-
nancy, childbirth, obesity, congenital or acquired connective tissue
abnormalities, chronic constipation, family history of POP, denervation
or weakness of the pelvic floor, the menopause and aging [2,5–9].
POP-related symptoms may vary based on the anatomical defect(s)
or in relation to the degree of bladder, bowel and sexual dysfunction
[1]. While many symptoms attributed to POP have a weak to moderate
correlation with a defect in pelvic organ support, moderate to advanced
POP is characterized by report of a vaginal bulge. The anatomic
threshold for symptomatic prolapse appears to be the hymen. Medical
attention is not frequently sought for early-stage POP, although it is
often identified in young and active women, who complain of sub-
jective impairment of their quality of life, particularly concerning their
sexual or work life, and physical activity [10].
Bladder and urethral function are frequently affected by loss of sup-
port of the anterior vaginal wall and apex. Symptoms of stress urinary
incontinence (SUI) often coexist with stage I or II anterior prolapse (as
defined below). However, as the anterior prolapse worsens, most women
see improvements in SUI and in fact may experience progressive voiding
impairment due to bladder outlet obstruction. In this circumstance,
women often report symptoms such as voiding hesitancy, prolonged or
intermittent flow, the need to push the POP up to aid voiding and the
sensation of incomplete bladder emptying. Women with POP also have an
increased risk of overactive bladder symptoms, such as urgency, urge
urinary incontinence, frequency and nocturia [11].
Defecatory symptoms are common in women with POP and may
occur with any defect of the posterior compartment, including recto-
cele, enterocele, sigmoidocele, internal rectal prolapse or full mucosal
rectal prolapse. Constipation, incomplete evacuation and obstructed
defecation are common complaints. Straining and the need to exert
digital manipulation to complete evacuation are clinical hallmarks of
obstructed defecation syndrome.
The evaluation of a patient with vaginal prolapse requires complete
assessments of the anatomical defect, of the full spectrum of pelvic floor
symptoms and of how these symptoms affect quality of life.
The use of a standardized system to describe POP is a key compo-
nent of treatment. The Pelvic Organ Prolapse Quantification (POP-Q)
system is internationally regarded as the standard for this purpose. It
provides a reproducible description of the support of the anterior,
posterior and apical vaginal segments using precise measurements to a
fixed reference point, the hymen, and established criteria for staging the
various levels of pelvic organ support from good support (POP-Q stage
0 or I) to almost complete lack of support (POP-Q stage IV). For the
further qualitative assessment of symptoms, a number of questionnaires
and instruments for condition-specific health-related quality of life
(HRQOL) are available and validated in different languages [12–15].
1.2. Age- and menopause-related modifications to the pelvic floor
Menopause is reckoned to be a key event associated with the
emergence or a worsening of POP. Symptoms and severity increase
significantly across the menopausal transition [7]. Despite this, it is
difficult to differentiate the specific contribution of estrogen with-
drawal from that of the aging process per se. Pelvic organs, and their
muscular and connective tissue supports, are estrogen-responsive.
The sensitivity of the urogenital tissues to sex steroid hormones has
been posited as an explanation for the frequent report of symptoms in
the lower urinary tract at the menopause. A panel of experts recently
incorporated this increased frequency of urinary tract symptoms into a
unifying concept called the genitourinary syndrome of menopause
(GSM) [16]. GSM is defined as a collection of symptoms and signs as-
sociated with a decrease in estrogen and other sex steroids; these
symptoms and signs include changes in the labia majora and minora,
clitoris, vestibule/introitus, vagina, urethra and bladder. The syndrome
may include but is not limited to: genital symptoms such as dryness,
burning and irritation; sexual symptoms such as lack of lubrication,
discomfort or pain, and impaired sexual function; and urinary symp-
toms such as urgency, dysuria and recurrent urinary tract infections.
Women may present with some or all of the signs and symptoms, which
must be bothersome and not attributable to another diagnosis [16].
While the creation of a new medical entity has been broadly debated
and criticized, it highlights how menopause does not affect solely va-
ginal tissues.
1.3. Impact of estrogen therapy on pelvic floor disorders
Withdrawal of estrogens during the menopausal transition results in
changes in the vagina and external genitalia that are collectively known
as vulvovaginal atrophy (VVA). Menopause is also associated with
significant changes in the low urinary tract and the pelvic floor. The
urethra and surrounding tissues, the bladder muscle and mucosa, and
the pelvic floor muscles all express estrogen receptors and become to
some extent dysfunctional in the absence of estrogens. Nearly 50% of
postmenopausal women have clinical symptoms related to VVA [17].
Any use of estrogens, orally, transdermally or vaginally, improves VVA.
While vaginal estrogen therapy provides symptomatic relief for ur-
ogenital atrophy, there is no evidence that it is beneficial in preventing
or limiting the progression of POP. Women are wary of estrogen
treatment: 41% of women have long-term safety concerns and 30% are
apprehensive about breast cancer. Nine percent of menopausal women
receiving a vaginal estrogen prescription never take the medication,
and those who do typically discontinue therapy after just 3 months.
This reluctance of women to use vaginal estrogens and physician dis-
inclination to recommend such therapy suggest either that such pre-
parations are not very effective or that their utility is underappreciated
[18].
A Cochrane systematic review published in 2010 regarding the role of
estrogens in preventing or treating female POP found scarce data in this
regard [19]. The only information from randomized trials comes from the
pooled data from trials of raloxifene carried out in postmenopausal
women aimed at preventing or treating osteoporosis; these studies re-
ported a decreased rate of prolapse surgery in women over 60 years of age
treated with raloxifene [19]. Studies evaluating the effect of local estro-
gens versus placebo or no treatment in women with POP have mainly
assessed VVA symptoms and signs rather than POP symptoms, and thus
provide little evidence on the clinical utility of such treatment in the
prevention or treatment of POP. A recent analysis from the Women’s
Health Initiative trial suggested that bilateral salpingo-oophorectomy at
the time of hysterectomy is not associated with increased risk of cystocele
or rectocele. Moreover, bilateral salpingo-oophorectomy and no sub-
sequent hormone therapy may have a protective effect against cystocele
or rectocele, thus confirming the evidence regarding estrogen therapy’s
limited effectiveness in the prevention and treatment of POP [20].
1.4. Perioperative use of estrogens in POP surgery
The evidence regarding the use of vaginal estrogen before prolapse
surgery is inconsistent. It is uncertain whether preoperative vaginal
estrogen is beneficial. The use of vaginal estrogens improves the vaginal
maturation index at the time of surgery and increases vaginal epithelial
thickness, but this does not translate into increased vaginal sub-epi-
thelial/muscularis thickness [18,21] and thus any possible surgical
advantages are to be proved. One study found that the use of vaginal
estrogens preoperatively decreases the frequency of bacteriuria after
surgery, but no difference in the incidence of symptomatic cystitis [22];
however, the study design does not allow for a comparison of the effect
of vaginal estrogens on other urinary complaints or on the integrity of
prolapse repair or wound healing [22].
Three studies have evaluated the use of vaginal estrogens after
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pelvic reconstructive surgery, with a total of 297 participants; overall,
the quality of the evidence was poor. There were net benefits with es-
trogen application after surgery, with decreased prevalence or severity
of urinary frequency and urgency, and less common granulation tissue
compared with placebo vaginal ring and other objective signs of
atrophy. The impact of local estrogen on prolapse recurrence, nocturia,
urgency urinary incontinence, urodynamic measures, or postoperative
urinary tract infection was uncertain. No studies were powered to de-
termine the effect of postoperative vaginal estrogen on surgical com-
plications such as mesh erosion. There were no significant adverse
events attributable to vaginal estrogen [23–25].
In conclusion, although vaginal estrogen is safe, there is limited
evidence that it can aid prolapse surgery by decreasing the likelihood of
early postoperative urinary tract infection and surgery-related symp-
toms.
2. Contemporary treatment of pop
Treatment of POP should be reserved for symptomatic women and
tailored to the individual woman’s symptoms; treatment of an asymp-
tomatic prolapse with a surgical intervention in particular should be
discouraged. Treatment of POP includes conservative management
(lifestyle modifications and physical therapies), surgery or pessaries.
The choice of approach must take into account the woman’s preference,
as well as her ability to comply with conservative therapy and to tol-
erate surgery.
2.1. Conservative management
• Lifestyle intervention and physical therapies
The first-line intervention for POP is conservative management,
which is usually a valid option for women with a mild degree of pro-
lapse and mild symptoms [26]. Lifestyle modifications include: dietary
changes, weight loss, reduction of activities that strain the pelvic floor,
treatment of constipation and cessation of smoking. While these inter-
ventions seem to mitigate POP symptoms, their effect on POP pro-
gression is still not established.
Physical therapies improve POP symptoms and help restore pelvic
floor function. These interventions include physical activity, cognitive
behavioral therapy, bladder training, bowel habit training, biofeedback
and electrical muscle stimulation [27]. Pelvic floor muscle training
involves the contraction of the pelvic floor muscles to improve strength,
endurance and timing of contractions in order to better support the
pelvic organs. Several meta-analyses show that women with sympto-
matic mild POP treated with pelvic floor muscle training undergo sig-
nificant improvement of prolapse symptoms and POP severity [28–30].
No data are available on the efficacy of pelvic floor muscle training in
aiding POP surgery, although most experts consider it useful [30,31].
2.2. CO2 Laser and Er:YAG laser (VEL)
Laser therapy has gained attention as an effective treatment for VVA
and is currently under scrutiny for its potential to improve urinary
continence and possibly pelvic support. Micro-ablative fractional CO2
laser and the non-ablative vaginal Er:YAG laser (VEL) induce mor-
phological changes in vaginal tissues through the generation of new
collagen. The largest body of data regarding laser therapy is on the
treatment of VVA [32,33]. Given its effects on collagen and pelvic floor
tissue, laser treatment shows promise as a non-surgical method for
treating mild POP and SUI [34–38]. At present, the data to support the
use of lasers for SUI and POP is limited. Randomized studies are needed
to compare different laser technologies, and to compare the effect of
laser treatment with other therapies, as well as to assess the duration of
the therapeutic effects and the safety of repeated applications [39].
2.3. Reconstructive surgery
Women with symptomatic prolapse who have failed conservative
management are candidates for reconstructive surgery. There is no in-
dication for the repair of asymptomatic POP as an isolated procedure. It
is important to identify symptoms that are attributable to each specific
anatomical compartment, since this aids surgical decision-making.
Several factors affect surgical planning, primarily the combination or
complexity of anatomical defects and the individual’s risks of surgical
complications. Isolated repair of anterior, posterior or apical vaginal
wall prolapse is typically performed transvaginally. Abdominal surgery
is more effective and safer for the management of advanced or multi-
compartmental POP.
• Anterior compartment surgery
Anterior vaginal wall POP may be due to central or lateral defects.
Central defects result from vertical defects in the endopelvic fascia.
Lateral defects result from detachment of the lateral vaginal wall from
the arcus tendineus fascia pelvis.
Anterior colporrhaphy is the procedure most commonly performed
for the management of anterior prolapse, independently from the lo-
cation of the fascial defect. Objective success rates range from 80% to
100% when anterior colporrhaphy is used to treat isolated cystocele
[40]. Anterior vaginal wall defects are often associated with descent of
the apex. Concomitant apical support increases long-term success when
compared with isolated anterior compartment repair [41].
Paravaginal repair (vaginal paravaginal or abdominal paravaginal)
for lateral defects is rarely performed and there are no randomized
trials to evaluate its outcomes.
Although the use of permanent meshes provides successful anato-
mical improvement of the anterior compartment and reduces the sub-
jective sensation of bulge when compared with anterior colporrhaphy,
prosthetic surgery is associated with serious complications, particularly
mesh exposures (11.3%), leading to a higher rate of reoperation (7%)
relative to native tissue repair [42,43]. Hence, the use of polypropylene
meshes as a first-line intervention for anterior compartment prolapse is
not recommended [43]. The use of absorbable meshes or biological
grafts in anterior compartment surgery may increase the success rate of
native tissue repair of anterior compartment defects, but this has not
been thoroughly investigated and biocompatible materials may be ex-
pensive [40].
• Posterior compartment surgery
Posterior vaginal wall prolapse can include high defects (vaginal
vault prolapse and enterocele) as well as middle and low rectoceles. The
repair of posterior vaginal prolapse can be addressed with vaginal,
transanal or abdominal approaches. There is an ongoing debate re-
garding the best approach to treat the different prolapses of the pos-
terior compartment, with differing views between gynecologists and
proctologists. It is now clear that rectocele is one of the many forms of
rectal prolapse, and when rectocele is associated with defecatory
symptoms a thorough proctological assessment should be undertaken
preoperatively. Surgical strategies to address posterior vaginal wall
prolapse should additionally aim to restore bowel function. Low rec-
toceles in the absence of defecatory symptoms, which often present
with an isolated bulging sensation, can be effectively treated with
transvaginal plication surgery.
Transvaginal repair of low rectocele is a good option in sympto-
matic (bulge) middle or low posterior vaginal wall prolapse. Traditional
posterior colporrhaphy with or without levator ani plication represents
the most common approach. Success rates range from 76% to 100%
[44]. Muscle plication should be avoided in sexually active women
because it frequently causes dyspareunia.
There is no indication for the use of biological grafts or
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polypropylene meshes as first-line strategies, as there is no evidence of
improved outcomes and there may be complications [2].
Transanal surgery, comprising plication strategies, is effective to
treat rectal prolapse or intussusception with defecatory dysfunction.
However, surgeons need to take into account anal sphincter function, as
these procedures may be associated with de novo gas or fecal incon-
tinence.
• Apical compartment surgery
Apical prolapse (uterus or vaginal vault) is often present in women
with prolapse; when it extends beyond the hymen, it is very bother-
some. Effective support of the apex is an essential element of any sur-
gical treatment for advanced POP [45]. Nonetheless, the management
of apical prolapse remains challenging. An abdominal approach with
prosthetic sacral colpopexy is considered the gold standard for the
treatment of apical defects. Abdominal sacral colpopexy is associated
with lower risks of recurrence (both awareness of prolapse on the part
of the patient, and prolapse evident upon examination), repeat prolapse
surgery, post-operative SUI and dyspareunia when compared with va-
ginal procedures [46].
2.3.1. Vaginal approach
A vaginal approach is a reasonable alternative to abdominal tech-
niques for women who cannot tolerate general anesthesia, those
without major risk factors for prolapse recurrence, and when con-
comitant vaginal surgery is required (for example to restore con-
tinence).
Vaginal surgical approaches for apical repair include sacrospinous
and uterosacral ligament suspension [47]. Vaginal hysterectomy with
uterosacral ligament suspension is the technique most commonly per-
formed for apical prolapse repair. When the apical defect coexists with
anterior or posterior defects, anterior colporrhaphy or posterior col-
porrhaphy can be performed at the same time. Removal of the uterus
helps to achieve apical suspension when a vaginal approach is used, as
it is technically simpler and more effective to attach the vaginal vault to
the uterosacral or sacrospinous ligaments than the cervix or the
isthmus. However, hysterectomy is not necessarily required for POP
reconstructive surgery. The majority of women are concerned about the
risks of hysterectomy and would prefer uterine conservation if it is
technically feasible, in order to maintain future fertility, or due to the
belief that cervix removal may affect sexual function, or, often, due to
the psychological identification of this organ with a sense of gender and
personal identity [48].
For women with mild uterine prolapse, the Manchester procedure
and sacrospinous hysteropexy are feasible and safe [49]. The Manche-
ster procedure is a good option to correct apical prolapse due to cervical
elongation in premenopausal women, since it preserves fertility. Sa-
crospinous hysteropexy seems as effective as vaginal hysterectomy, but
reduces operating time, blood loss and recovery time [50]. However,
long-term data are limited and the need for subsequent hysterectomy is
unknown.
Nevertheless, women with advanced apical prolapse have a higher
risk of recurrence when treated transvaginally, particularly if uterine
preservation is desired; therefore, abdominal procedures are best in
such circumstances.
2.3.2. Abdominal approach
Abdominal sacral colpopexy is the gold standard for the manage-
ment of advanced apical defects [46]. Although the majority of out-
come studies regarding abdominal sacral colpopexy used an open
technique, laparoscopic and robot-assisted approaches are now more
commonly performed, since they combine efficacy with minimization
of surgical invasiveness. Data suggest that the conventional laparo-
scopic and robot-assisted laparoscopic approaches result in a shorter
hospital stay, faster recovery time, a significant decrease in blood loss,
and less postoperative pain than laparotomy, but have comparable
short-term efficacy, ranging between 85% and 100% [51]. Robotic
surgical systems have been developed with the goal of facilitating
technically difficult procedures by improving the surgeon’s vision,
dexterity and ergonomics. The technical advantages conferred by the
robotic platforms are particularly useful in pelvic floor reconstructive
surgery, and the introduction of new devices is likely to have a pro-
found impact in this field. Although further studies are necessary to
clarify the possible advantages of robotic versus laparoscopic abdom-
inal sacral colpopexy, the data so far suggest that the laparoscopic route
may be more cost-effective and confer more benefit to women [51–54].
However, the studies suffer from a lack of standardization of robotic
procedures and sample sizes are small. Larger datasets will become
available as robotic surgery becomes more widely disseminated, which
will allow firmer conclusions to be drawn.
Lateral apical mesh suspension to the abdominal wall is a recently
developed surgical approach that effectively treats advanced apical
prolapse while avoiding pre-sacral dissection and the related compli-
cations. Lateral apical mesh suspension is a safe and simpler technique
than abdominal sacral colpopexy and it seems to be highly effective
[55–59]. However, a trial comparing lateral apical mesh suspension
with abdominal sacral colpopexy for the treatment of apical prolapse is
currently not available.
2.3.3. Transvaginal prosthetic surgery
Transvaginal mesh kits are highly effective in restoring apical pro-
lapse [46]. However, in July 2011, the US Food and Drug Adminis-
tration (FDA) classified transvaginal meshes used for prolapse as high-
risk devices, and they lost popularity. The main concern raised by the
FDA is related to vaginal pain, dyspareunia and mesh erosions and
infections, which are not rare in women treated with these devices.
Many transvaginal mesh kits were removed from the market following
the FDA alert. Newer, lighter-weight transvaginal meshes are now
available; however, to date, no data show a lower rate of complications
with these newer materials [60].
Nonetheless, there is a select group of women who are good can-
didates for the use of transvaginal meshes in the hands of specialist
surgeons trained in SUI and pelvic floor reconstructive surgery, in-
cluding the use of specific transvaginal synthetic mesh prolapse kits and
the treatment of potential mesh-related complications [60–69]. It is
essential that the surgeons provide information about the risks and
benefits of transvaginal mesh procedures so that women can review all
the treatment options available to them and participate actively in
decision-making.
Currently, transvaginal meshes should be used only in research
contexts [70], in complex cases or to treat recurrent prolapse, when
other strategies are not feasible or are clearly less effective [71].
The relatively high rate of mesh-related complications associated
with their transvaginal use has not been observed with abdominal ap-
proaches using the same synthetic meshes. Abdominal procedures are
associated with erosion (albeit rarely, in 0–8% of cases), which are
mostly observed when total hysterectomy is performed with immediate
attachment of a mesh to the sutured vaginal vault [72]. This suggests
that bacterial mesh contamination at the time of vaginal introduction is
the main reason for the higher rate of mesh-related complications seen
with transvaginal kits.
2.4. Obliterative surgery and pessaries
The choice of reconstructive procedures in preference to obliterative
procedures depends upon the clinician’s medical skills and the woman’s
sexual function.
Total colpocleisis or LeFort partial colpocleisis corrects POP by
closing off the vaginal canal either in part or entirely [73]. Obliterative
procedures are reserved for elderly, frail women with advanced POP,
who cannot have extensive surgery and do not wish to conserve sexual
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function. Colpocleisis provides good relief of pelvic floor symptoms and
has low rates of morbidity [47]. The anatomical success rate of these
procedures is 90%.
Vaginal pessaries are a safe and effective option for women with
POP as an alternative to surgery for symptomatic elderly women, or for
women who wish to become pregnant, or for those who prefer a non-
surgical treatment. Pessaries are also commonly used in women re-
quiring symptomatic relief while awaiting surgery. Pessaries are sili-
cone devices that are inserted into the vagina to keep the prolapsed
organs in their normal position and hence relieve symptoms. Two main
types of vaginal pessaries are used: support and space-filling pessaries
[27]. There is evidence of their effectiveness from several randomized
controlled trials and observational studies. Complications are usually
minor, vaginal discharge being the most common [27,74,75]. There is
no consensus on the use of different types of pessaries for specific types
of prolapse, nor on the pattern of replacement, the treatment of com-
plications and appropriate length of follow-up [76].
3. Conclusions
The burden of POP on women’s health is rising as life expectancy is
increasing. POP can be devastating, disrupting social, sexual and daily
activities. Healthcare professionals in the field of menopause are in a
key position to identify the problem, to characterize it, and either to
manage it themselves or to refer women appropriately. POP manage-
ment is challenging and requires advanced skills, particularly when
surgery is required. POP should not be ignored and women should be
informed of the available treatments and participate actively with their
healthcare professional in making management decisions. Clinical ser-
vices should be able to offer up-to-date non-surgical and surgical op-
tions in order to satisfy treatment demands for this growing problem
and to help women enjoy their later years.
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